What Is Tirzepatide? GIP + GLP-1 Dual-Agonist Explained

What Is Tirzepatide?

Tirzepatide is a synthetic injectable medication developed by Eli Lilly. It belongs to the GLP-1 drug class (the same class as semaglutide, sold as Ozempic and Wegovy), but with a key difference: it targets two hormone receptors instead of one. It activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This is why it's called a dual agonist. You can find a full overview of tirzepatide's clinical profile on the tirzepatide hub page.

Chemically, tirzepatide is a 39-amino acid peptide with a C20 fatty diacid chain attached. That fatty chain allows it to bind to albumin (a protein in your blood), which gives it a long half-life of roughly 5 days and allows once-weekly dosing. After a subcutaneous injection, it reaches peak plasma levels within 8–72 hours and achieves stable steady-state concentrations after about 4 weeks of weekly injections.

The Basics at a Glance

• Generic name: Tirzepatide
• Manufacturer: Eli Lilly and Company
• Drug class: Dual GIP/GLP-1 receptor agonist
• Administration: Once-weekly subcutaneous injection
• Approved doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
• Half-life: ~5 days (120 hours); steady state in ~4 weeks
• Brand names: Mounjaro (T2DM), Zepbound (obesity, sleep apnea)
• FDA status: ✅ Fully approved

How the Dual-Agonist Mechanism Works

To understand tirzepatide, you need to understand two gut hormones: GLP-1 and GIP. Both are released naturally after you eat. They signal the pancreas to produce insulin and help regulate how much you eat and how your body stores energy. Tirzepatide mimics both, but with an important twist.

Research shows tirzepatide has a higher affinity for the GIP receptor than even native GIP itself, while having a somewhat lower affinity for the GLP-1 receptor than native GLP-1. This "imbalanced" agonism is deliberate. It's part of what makes tirzepatide behave differently from a pure GLP-1 drug like semaglutide.

GLP-1 receptor: appetite suppression and insulin

The GLP-1 receptor is the engine behind appetite suppression. When tirzepatide activates it, several things happen at once. The pancreas produces more insulin, but only when blood glucose is already elevated, so hypoglycaemia is uncommon in people without diabetes. Glucagon (a hormone that raises blood sugar) is suppressed. Gastric emptying slows, so food stays in your stomach longer, keeping you feeling full. Hypothalamic satiety signals in the brain are activated, reducing hunger.

GIP receptor: the additional layer

The GIP receptor is where tirzepatide goes beyond standard GLP-1 therapy. GIP receptor activation adds further insulin secretion from the pancreas and appears to have effects on fat tissue and insulin sensitivity. However, the precise mechanism by which GIP activation contributes to tirzepatide's greater weight loss (compared to GLP-1 alone) is still being studied. Preclinical data suggests roles in adipose tissue metabolism and possibly increases in adiponectin (an insulin-sensitising hormone), but strong primary human trial evidence for these pathways is not yet established. Scientists know the combination works better; they're still working out exactly why.

What Is Tirzepatide FDA-Approved For?

Tirzepatide holds three distinct FDA approvals across two brand names. The scope of those approvals has expanded rapidly since 2022.

Mounjaro: type 2 diabetes

The FDA approved Mounjaro for type 2 diabetes in adults in May 2022. It is indicated as an adjunct to diet and exercise to improve blood sugar control. In 2025, the approval was extended to children aged 10 and older with type 2 diabetes. Mounjaro is not approved for type 1 diabetes.

Zepbound: chronic weight management

Zepbound received FDA approval for weight management in November 2023. The eligibility criteria mirror most GLP-1 obesity indications: a BMI of 30 or higher, or a BMI of 27 or higher if you have at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Zepbound is the same molecule as Mounjaro: same doses, same injection device, just with a separate brand name and obesity indication.

Zepbound: obstructive sleep apnoea

In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity, the first medication ever approved for this condition. The approval was based on the SURMOUNT-OSA Phase 3 trials, which showed significant reductions in the apnoea-hypopnoea index (AHI) versus placebo. Much of the OSA benefit comes from weight reduction rather than a direct drug effect on airway physiology.

Clinical Trial Results: What the Data Shows

Tirzepatide's efficacy is backed by some of the largest and most recent weight loss trials in the class. Here are the key trials.

SURMOUNT-1: Weight Loss Without Diabetes

SURMOUNT-1 enrolled 2,539 adults with obesity but no type 2 diabetes. Participants were randomised to tirzepatide (5mg, 10mg, or 15mg) or placebo for 72 weeks. At the highest dose (15mg), the mean body weight loss was 20.9% versus 3.1% with placebo. Ninety-one percent of those on 15mg achieved at least 5% weight loss. Nearly a third achieved 30% or more.

SURMOUNT-5: Head-to-Head vs Semaglutide

SURMOUNT-5 is the most important trial for contextualising tirzepatide against semaglutide (Wegovy). It enrolled 751 adults with obesity (no T2DM) and randomised them to tirzepatide (up to 15mg) or semaglutide (up to 2.4mg) for 72 weeks. The result was clear: tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide , a 47% greater relative reduction. Nearly twice as many tirzepatide participants achieved 25% or more weight loss (31.6% vs 16.1%).

SURPASS-2: Type 2 Diabetes vs Semaglutide

In patients with type 2 diabetes (1,879 participants, 40 weeks), tirzepatide outperformed semaglutide 1mg on both blood sugar control and weight loss. HbA1c (a 3-month blood sugar average) fell by 2.01–2.30 percentage points with tirzepatide versus 1.86 pp with semaglutide, and all tirzepatide dose groups were superior (p<0.001).

How Tirzepatide Is Taken

Tirzepatide is a once-weekly subcutaneous injection, administered in the abdomen, thigh, or upper arm. The starting dose is always 2.5mg for the first four weeks. It is not a therapeutic dose; its purpose is to let your gastrointestinal system adjust before moving to higher doses. You then increase by 2.5mg every four weeks, as tolerated.

Standard titration schedule

The four-week intervals match the drug's half-life. Waiting roughly four weeks before increasing the dose lets your body reach steady state (stable blood levels) at the current dose before adding more. This makes it easier to distinguish dose-related side effects from normal fluctuation. Not everyone needs to reach 15mg; many people achieve their goals at 10mg or 12.5mg.

For compounded tirzepatide (available as a lyophilised powder rather than a pre-filled pen), you will need to reconstitute the vial with bacteriostatic water before injecting. Use the tirzepatide calculator to plan your schedule and our reconstitution tool to calculate the exact number of insulin units to draw. For full protocols, see the tirzepatide dosing guide.

Tirzepatide vs Semaglutide: What Is the Difference?

This is one of the most common questions about tirzepatide. The answer comes down to receptor targets and trial data.

Semaglutide is a GLP-1 mono-agonist. It targets one receptor. Tirzepatide targets two: GLP-1 and GIP. In practice, that additional GIP receptor activation appears to produce meaningfully more weight loss. SURMOUNT-5, which randomised participants to either drug directly, showed a 47% greater relative weight reduction for tirzepatide.

The safety profiles are broadly comparable. GI side effects (nausea, diarrhoea, constipation) occur at similar rates in SURMOUNT-5. The main practical differences are the mechanism, the degree of weight loss, and tirzepatide's additional OSA indication. For a full comparison, see the tirzepatide vs semaglutide comparison guide.

Side Effects: What to Expect

Tirzepatide's side effects are dominated by gastrointestinal symptoms, the same pattern seen across the entire GLP-1 drug class. The main driver is slowed gastric emptying: food moves more slowly through your digestive system, which causes nausea for many people, especially early on.

Most Common Side Effects

• Nausea: most frequent, particularly in the first few weeks at each new dose
• Diarrhoea: common, typically early in treatment or after dose increases
• Constipation: can alternate with diarrhoea as your GI tract adapts
• Vomiting: usually linked to eating too fast or too much while nausea is active
• Decreased appetite: desired for weight loss, but can lead to inadequate caloric intake if not managed

These effects are most intense during the initiation phase and at each dose increase. They typically improve within 2–4 weeks as your body adapts. Eating smaller portions, avoiding high-fat meals, and eating slowly all help.

Serious Risks to Know

Other serious but uncommon risks include pancreatitis (inflammation of the pancreas; stop the drug and seek care if you develop severe abdominal pain), gallbladder disease, acute kidney injury (usually from dehydration), and hypoglycaemia if combined with insulin or sulfonylureas. For a detailed breakdown of incidence rates and management strategies, see the tirzepatide side effects guide.

What About Compounded Tirzepatide?

Compounded tirzepatide is a pharmaceutical-grade version mixed by a licensed compounding pharmacy and dispensed with a prescription. During the period when branded tirzepatide appeared on the FDA drug shortage list, compounding was permitted under specific FDA regulations. Many people who self-administer compounded GLP-1s use tirzepatide in this form: a lyophilised (freeze-dried) powder reconstituted with bacteriostatic water.

The pharmacology is identical to the branded product. The key difference is the delivery format (vial + syringe vs pre-filled pen) and the sourcing. If you are using compounded tirzepatide, the tirzepatide dosing calculator will help you model your schedule, and the reconstitution calculator handles the unit conversions for each dose.

Some users also explore microdosing tirzepatide, which splits the weekly dose into smaller, more frequent injections to reduce peak-related nausea. This is an off-label approach not covered by the clinical trials.